title: Microbiota and nonalcoholic steatohepatitis.
abstract: The recent rise in obesity-related diseases, such as nonalcoholic fatty liver disease and its strong association with microbiota, has elicited interest in the underlying mechanisms of these pathologies. Experimental models have highlighted several mechanisms connecting microbiota to the development of liver dysfunction in nonalcoholic steatohepatitis (NASH) such as increased energy harvesting from the diet, small intestine bacterial overgrowth, modulation of the intestinal barrier by glucagon-like peptide-2 secretions, activation of innate immunity through the lipopolysaccharide-CD14 axis caused by obesity-induced leptin, periodontitis, and sterile inflammation. The manipulation of microbiota through probiotics, prebiotics, antibiotics, and periodontitis treatment yields encouraging results for the treatment of obesity, diabetes, and NASH, but data in humans is scarce.
authors: Division of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
authors: Kento
authors: K
authors: Imajo
authors: Masato
authors: M
authors: Yoneda
authors: Yuji
authors: Y
authors: Ogawa
authors: Koichiro
authors: K
authors: Wada
authors: Atsushi
authors: A
authors: Nakajima
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D005234:Fatty Liver / Q000209:etiology*; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000382:microbiology; D007422:Intestines / Q000382:microbiology; D064307:Microbiota; D009055:Mouth / Q000382:microbiology; D065626:Non-alcoholic Fatty Liver Disease; D010518:Periodontitis / Q000188:drug therapy; D056692:Prebiotics; D019936:Probiotics
chemical_list: D000900:Anti-Bacterial Agents; D056692:Prebiotics